Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets widen losses
Tue, 26 Feb 01:30 pm

As selling pressure intensified, Indian share markets nosedived further in the post-afternoon trading session. Majority of the sectoral indices are trading negative with oil and gas, auto and capital goods stocks being the biggest losers. Only FMCG and IT stocks are trading in green.

BSE-Sensex is down 194 points and NSE-Nifty is trading down by 59 points. While BSE Mid Cap is down 1.4%, BSE Small Cap index is down by 1.8%. The rupee is trading at 54.1 to the US dollar.

Majority of the FMCG stocks are trading in red with Archies and Bata India being the major losers. However, Hindustan Unilever and Dabur are trading strongly. As per a leading financial daily with consumer demand showing signs of moderation, FMCG companies have been raising ad-spends to boost consumption and gain market share. Recently FMCG behemoth Hindustan Unilever (HUL) filed a case against the Indian subsidiary of Reckitt Benckiser for denigrating its Vim product in a comparative advertisement of the latter's Dettol Kitchen dishwashing liquid. Even Colgate-Palmolive started an aggressive advertisement campaign of its gum toothpaste after Glaxo SmithKline Consumer Healthcare launched global brand Parodontax in the Indian market. As per Advertisement Standards Council of India (ASCI), the best way for an entrant to capture market share is to claim superiority and if the claims are based on facts then it is legitimate as it provides consumers with more information about the products they are using. Advertisement agencies see an escalation in ad-spends among consumer companies going forward.

Most of the domestic pharma stocks are trading are in red with Panacea Biotech and Dishman Pharma being among the top losers. Mylan, a US based generic company has announced launch of Antara generics. This drug is equivalent to Lupin's brand Antara, which generates annual revenues of around $60 m in US as per the report. Lupin was in litigation with Mylan and other generic companies over this drug. Mylan had received USFDA approval on this drug some time back. It is still not clear whether, Mylan's launch is "at risk" or not. Antara is part of Lupin's branded portfolio and is among the important contributor to the company's top line. Lupin was trading down by 2.0%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets widen losses". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.